1) Is a membrane filtration method for validation of bioburden in 
disinfectant solutions covered by the 'membrane filtration methods' in 
the European and United States Pharmacopoeia? 
2) Which environmental isolates would we challenge the method with if 
our production environment surface contact plates very rarely show 
growth? Is it acceptable to use only the organisms listed as for bulk 
bioburden methods in the EP/USP? 

Martin Sarosi
on behalf of Pharmig

http://www.pharmig.org.uk/


------------------
The PMFList (http://microbiol.org/PMFList_info.htm) is operated from
The Microbiology Network (http://microbiol.org) and supported by
our sponsors (http://microbiol.org/sponsor.htm) as a service to
the scientific community.